Arrowhead’s Plozasiran Cuts Acute Pancreatitis Risk by Up to 100% in Phase 3 Severe Hypertriglyceridemia Trials Arrowhead plans sNDA filing by end of 2026. Credit: Arrowhead Pharmaceuticals Subscribe now Already have an account? Sign in.
